

David S. Perlin, Ph.D.

Chief Scientific Officer/ Senior Vice President

Center for Discovery and Innovation- Hackensack Meridian Health

340 Kingsland Street, Nutley, NJ 07110

Tel: 201-880-3101; Email: david.perlin@hmh-cdi.org; Website: <https://hmh-cdi.org/>

Fellow, New York Academy of Sciences; Fellow, American Academy of Microbiology

Dr. David Perlin is a highly-accomplished biomedical researcher, senior administrator and recognized leader in combatting antibiotic and antifungal drug resistance. He recently (January 2019) assumed the position of inaugural Chief Scientific Officer for the Hackensack Meridian Health Center for Discovery and Innovation (CDI), which was developed as an applied research enterprise to rapidly translate innovations in science to improve outcomes for patients with cancer and infectious diseases. Dr. Perlin has been engaged for more than 25 years in developing molecular insights and technologies to detect, combat and prevent drug resistant bacterial and fungal infections. He has helped develop novel therapeutics and diagnostics, some of which are commercial products, and developed a wide range of domestic and global programs addressing both hospital- and community-associated drug resistance. His group has developed molecular diagnostic products for the CDC and local hospitals for multidrug resistant outbreak pathogens including drug resistance determinants. He has participated in diagnostic and therapeutic guidance meetings on behalf of device manufacturers and Pharma with the FDA and EMA. He also serves as an advisory board member to numerous Pharma, biotech and diagnostic companies for development of novel therapeutics and diagnostics targeting drug resistant pathogens.

Dr. Perlin has published more than 250 papers and book chapters, and has co-authored two books. His laboratory has been supported by multiple grants from the NIH, DoD, Pharma, biopharma and foundation sectors. The NIH has continuously funded him for 30+ years, and he leads a newly awarded (re-compete) NIH-designated national Center of Excellence in Translational Research (CETR) to discover novel antibiotics against drug resistant bacterial infections¹. In this capacity, he leads five drug discovery programs and has recently supported novel drug discovery platforms for 12+ companies. He also provides support for the CARB-X Global Accelerator Network via the Institute for Life Science Entrepreneurship (*ILSE*). Apart from the CETR program, he leads an NIH-sponsored antibiotic discovery program to develop novel topoisomerase-gyrase inhibitors against drug resistant *Neisseria gonorrhoea*; he has two R01 grants to perform IND-enabling studies for novel antibody drug conjugates against multidrug resistant Gram negative pathogens; and has an RO1 examining genetic factors contributing to the emergence of multidrug resistance among *Candida glabrata*. He is widely regarded as a global leader in antifungal drug resistance and fungal molecular diagnostics, and he leads the Astellas Global Reference Center for echinocandin and azole resistance among fungi. Most recently, his group elucidated the molecular mechanisms for drug resistance among clinical isolates of *C. auris*, and developed the first comprehensive rapid diagnostic test for pathogen identification and drug resistance. His group has been working closely with the CDC on this epidemic in New York and New Jersey, and other global health departments.

Prior to joining the CDI, he served for nearly two decades as Executive Director of the Rutgers New Jersey Medical School's Public Health Research Institute (PHRI), a 77-year-old specialized center for global infectious diseases. He was also Director of the Rutgers Regional Biocontainment Laboratory (RBL), one of thirteen NIH-designated national centers for high-threat pathogen research, and a Professor of Microbiology, Biochemistry and Molecular Genetics. As PHRI's Scientific Director and then Executive Director, he oversaw PHRI's programs to address multidrug resistant bacterial and fungal pathogens locally and abroad.

Dr. Perlin serves on the Board of Directors of the Aaron Diamond AIDS Research Center (ADARC), and Scientific/Medical Advisory Boards for the Clinical Laboratory Standards Institute (CLSI), Pharma and biotech companies, as well as numerous editorial boards. Dr. Perlin is a Fellow of the American Academy of Microbiology (2018) and the New York Academy of Sciences (2006).